Ryan C Sullivan

US Patent:

20210262008, Aug 26, 2021

Filed:

May 6, 2021

Appl. No.:

17/313938

Inventors:

- Tucson AZ, US
Inna Gladysheva - Phoenix AZ, US
Ryan Sullivan - Phoenix AZ, US
Ranjana Tripathi - Phoenix AZ, US

International Classification:

C12Q 1/37
A61K 31/16
G01N 33/573
A61P 9/04

Abstract:

Methods of using measured plasma renin activity assayed (PRA), plasma renin activity concentration (PRAC), active renin concentration (ARC), plasma renin activity concentration (PRAC) and/or active plasma renin concentration (APRC), pro-renin activity, (pro)-renin receptor (PRR) levels for diagnosing, prognosing, treating and monitoring heart failure (HF) or HF-associated conditions or other conditions that cause or are caused by altered (e.g., elevated) renin activity, pro-renin levels, PRR levels, PRC, APRC, and/or interaction of renin or pro-renin with PRR. These methods can be used for at-risk patients for personalized therapy of heart disease to reduce heart dysfunction progression, diminish HF, and prolong life. This technology stratifies patients with HF or those at risk for HF to determine the appropriate medication (agents that specifically interfere with plasma renin activity/pro-renin and/or PRR) or intervention and the appropriate dosage of medication to treat further HF progression.

US Patent:

20210263120, Aug 26, 2021

Filed:

May 6, 2021

Appl. No.:

17/313904

Inventors:

- Tucson AZ, US
Inna Gladysheva - Phoenix AZ, US
Ryan Sullivan - Phoenix AZ, US
Radhika Mehta - Phoenix AZ, US

International Classification:

G01R 33/48
A61B 5/00
A61B 5/055

Abstract:

Methods of utilizing quantitative magnetic resonance (QMR) to non-invasively determine and quantify body fluid dynamics [e.g., extracellular water and total water levels] and body compositions (e.g., lean muscle mass and fat mass levels). These levels or changes therein are used as biomarkers to diagnose, prognose, tailor and monitor treatment for conditions that cause or caused by ECW retention (edema), lean muscle mass loss (sarcopenia), and/or fat loss (cachexia), including heart failure (HF) and HF-associated and HF-non-associated edema/sarcopenia/cachexia, kidney disease, liver disease, and other HF complications. Body fluid dynamics and body compositions measurements obtained from QMR technology are used as biomarkers to help a physician's assessment to determine the prognosis and personalized treatment strategies that are tailored for individual patients with heart dysfunction and/or HF, HF-associated conditions, and/or other conditions that cause or caused by edema, sarcopenia, and/or cachexia.